156 results about "Traumatic Stress Disorders" patented technology

The invention provides a virtual reality training system and method for fireman stress disorder adjuvant therapy, the fireman training system and method based on virtual reality are provided by utilizing the development of the virtual reality technology and the heart rate variability monitoring technology, the virtual reality environment is selected and adjusted in combination with multiple dimensions, and the fireman stress disorder adjuvant therapy effect is improved. On one hand, the fire-fighting task processing capability of the firefighter can be trained, and on the other hand, the post-traumatic stress disorder of the firefighter can be treated in an auxiliary manner, so that the firefighter is helped to overcome the fear of trauma and high pressure in the fire-fighting task, and the post-traumatic stress disorder is prevented and treated in an auxiliary manner; the cure rate of the stress disorder of the group of firemen is effectively improved, and the prevalence rate of the stress disorder is reduced. Moreover, according to the scheme, through multi-level personalized adjustment, it is ensured that the adjuvant therapy training scheme better meets the unique requirements of each fireman according to individual characteristics, individual differences, psychological states and physiological states, and the training effect is effectively improved.

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

Approaches presented herein provide for automatic detection and remediation of various undesired states or behaviors of a user using an electronic device. Embodiments allow for detection of high levels of anxiety (as might be associated with post-traumatic stress disorder (PTSD)) of the user and initiating calming mechanisms to attempt to reduce a level of anxiety in the user. Aspects of the user can be monitored and analyzed to determine a level of anxiety, stress, etc., of the user. Such analysis can be performed using a machine learning model that is trained to infer a level of anxiety of a user based on a variety of possible inputs. If the user is determined to likely be in a high anxiety state, one or more calming mechanisms or adjustments can be made automatically in order to attempt to reduce the level of anxiety being experienced by the user.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

The present invention relates to a mental disease prediction and diagnosis classification apparatus by means of a natural language expression and a method therefor. According to the present invention, the mental disease prediction and diagnosis classification apparatus comprises: an input unit that receives, as an input from a medical personnel terminal, mental disease natural language expression information of a patient to be diagnosed; a preprocessing unit that tokenizes the mental disease natural language expression information by using a natural language processing (NLP) algorithm; and a disease prediction unit that inputs the tokenized mental disease natural language expression information into a pre-built diagnosis classification model to classify the corresponding patient to be diagnosed as having any one mental disease from among a generalized anxiety disorder, a panic disorder, a post-traumatic stress disorder, obsessive-compulsive thought or rumination, a remarkable obsessive-compulsive behavior, a social phobia, a specific phobia, agoraphobia, an adjustment disorder, an acute stress response, and a mixed obsessive-compulsive thought and behavior.

A method, computer-readable media, and system associated with psychiatric and physiologic monitoring of a patient having PTSD or anxiety-related mental health conditions are provided. For example, data associated with a survey or questionnaire that was provided to a patient is received. A score may be determined from the data associated with the survey or questionnaire. A time-series is formed using heart-rate measurements detected by a sensor. Fractal properties, such as a Hurst exponent, may be calculated for the time-series. The score may be contextually matched to a set of reference scores. Further, the contextual matching may be used to determine a range of normative HRV values for determining whether a value associated with the patient is within the range. If the value associated with the patient is not within the range, a notification may be provided.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

The disclosure relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), panic disorder, anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).

The present application describes compositions comprising 5-MeO-DMT, one or more diluents, and optionally a cannabinoid compound for inhalation through vaporization. In certain embodiments, the compositions can be utilized as a treatment of trauma-related disorder or stressor-related disorder, such as post-traumatic stress disorder (PTSD), acute stress disorder (ASD), reactive attachment disorder (RAD), and disinhibited social engagement disorder (DSED). In particular embodiments, the composition comprises about 15-45% 5-MeO-DMT and 15-35% CBD dissolved in triethyl citrate or alpha-bisabolol, which has been observed herein to effectively remedy patients' anxiety and stress.

The invention discloses an application of simvastatin in preparation of a medicine for treating post-traumatic stress disorder. According to the invention, a post-traumatic stress disorder model is firstly constructed, and a result shows that in post-traumatic stress disorder model animals, obvious core behavior characteristics such as fear memory overconsolidation and anxiety behavior enhancement are shown. When simvastatin is used for intervention treatment, the fear memory fading ability of the model animal is obviously improved, and the anxiety behavior is obviously relieved; behavior experiment comprehensive evaluation shows that the stiffness time of animals in a simvastatin treatment group is remarkably shortened, the standing time and distance proportion of an open arm of an elevated cross maze are remarkably increased, the total movement distance of an open field experiment is remarkably increased, and simvastatin can effectively relieve fear memory disorder and anxiety behaviors of post-traumatic stress disorder model animals.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. The compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. The use of compound C having formula (I'), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the preparation of pharmaceutical compositions for the treatment or prevention of disorders for which ASIC inhibitors are indicated is also provided. In some embodiments, pharmaceutical compositions prepared using the compound of formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or compound C, are for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511139000245.jpg21170

Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment of anxiety and related conditions, including Generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, anxious depression, and phobias, the methods comprising administering to the subject a therapeutically effective amount of a compound.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

The present invention relates to a crystalline microparticle form of 6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl)propyl)thieno[2,3-b]pyridine-5-carboxamide potassium salt (PRX-3140) (I) for a particle delivery system (PDS) having good bioavailability and stability for the treatment of Alzheimer's disease (AD) and other dementias including post-traumatic stress disorder (PTSD) that affect the cholinergic and / or serotonergic systems. In other aspects, the present invention relates to an oral dosage form, a method of synthesizing the crystalline microparticle form, the preparation of a particle delivery system (PDS), and a final dosage form (FDF). JPEG2025518713000025.jpg49169

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

Disclosed in the present application is the use of ritonavir in the preparation of a drug for treating a psychological disorder caused by a traumatic event. In the present application, it is found that intraperitoneal injection of ritonavir to fear memory extinction resistant model mice (AtLAS- / - mice) and extinction resistant (EXT-R) mice distinguished from common C57BL6 mice can significantly relieve the rigidity of the model mice and EXT-R mice. It is further confirmed by means of immunoblotting and co-immunoprecipitation methods that ritonavir can significantly block the binding of Syn2a to Syngr-3 and promote the formation of a trimer of VAMP2, Syntaxin and SNAP25 to promote and restore the normal release of presynaptic membrane vesicles in neurons, so as to restore the rigidity of the extinction resistant model mice and EXT-R mice, and treat a psychological disorder, such as post traumatic stress disorder (PTSD), caused by a traumatic event.

The application provides a traditional Chinese medicine composition for preventing post-traumatic stress disorder and a preparation method thereof. The traditional Chinese medicine composition for preventing post-traumatic stress disorder comprises the following raw materials in parts by weight: 10-20 parts of ginseng and 10-20 parts of rhizoma polygonati, and in addition, 15-25 parts of mulberry, 15-25 parts of hawthorn and 5-15 parts of raphanus sativus. The traditional Chinese medicine composition is reasonably matched, has the effects of nourishing heart and soothing nerves, benefiting qi and nourishing blood, invigorating spleen and benefiting stomach and can well play a role in preventing post-traumatic stress disorder.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity / weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory / autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

The present disclosure relates to compounds of Formula I that exhibit 5-HT2A receptor agonist activity and low 5HT2B receptor agonist activity or deemed 5HT2B receptor agonist inactivity. In at least some cases, such compounds show selectivity for the 5-HT2A receptor over the 5-HT2C receptor. As contemplated herein, phenethylamines may be used for the treatment of neuropsychiatric, neurodegenerative, neuroinflammatory and pain disorders including depression, drug (e.g. tobacco, opiate, and cocaine) addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

Disclosed is a pharmaceutical composition for preventing or treating a mental disorder. More specifically, disclosed is a pharmaceutical composition for treating or preventing a mental disorder, including substance-related and addictive disorder, depressive disorder, anxiety disorder, or post-traumatic stress disorder, by using a compound that simultaneously regulates mGluR5 and 5-HT2AR.

This application discloses the use of ritonavir or its derivatives in the preparation of medicaments for treating mental disorders. This application also discloses the discovery of mice (AtLAS) with difficulty in extinction of fear memories. ‑ / ‑ Intraperitoneal injection of ritonavir significantly restored the rigidity rate in model mice. Further immunoblotting and co-precipitation confirmed that ritonavir could significantly block the binding of Syn2a and Syngr-3, and promote the formation of VAMP2, Syntaxin, and SNAP25 trimers, thereby promoting the normal release of presynaptic membrane vesicles in neurons and restoring the rigidity rate in mice with refractory rigidity, thus achieving the treatment of mental disorders such as post-traumatic stress disorder.